Pfizer Inc. (NYSE:PFE) Shares Sold by Wealth Advisors of Tampa Bay LLC

Wealth Advisors of Tampa Bay LLC reduced its position in Pfizer Inc. (NYSE:PFE - Free Report) by 50.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 73,570 shares of the biopharmaceutical company's stock after selling 74,043 shares during the quarter. Wealth Advisors of Tampa Bay LLC's holdings in Pfizer were worth $1,952,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of PFE. Norges Bank purchased a new stake in Pfizer in the 4th quarter valued at approximately $2,328,986,000. Charles Schwab Investment Management Inc. grew its holdings in Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after acquiring an additional 25,315,159 shares during the period. Raymond James Financial Inc. purchased a new position in Pfizer in the fourth quarter worth $274,694,000. Massachusetts Financial Services Co. MA lifted its holdings in Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock valued at $2,029,604,000 after acquiring an additional 5,350,381 shares during the period. Finally, Fisher Asset Management LLC boosted its position in shares of Pfizer by 79.5% during the 4th quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company's stock worth $295,760,000 after purchasing an additional 4,938,209 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of PFE stock traded down $1.30 during trading hours on Friday, reaching $22.99. The stock had a trading volume of 79,829,399 shares, compared to its average volume of 39,460,357. The firm has a market capitalization of $130.39 billion, a PE ratio of 16.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The firm has a 50-day simple moving average of $25.87 and a 200-day simple moving average of $26.74. Pfizer Inc. has a twelve month low of $22.95 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the previous year, the company posted $0.10 earnings per share. The business's revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Bank of America restated a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.